Advertisement
Research Article

HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer

  • Merel Gijsen,

    Affiliation: Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

    X
  • Peter King,

    Affiliation: Oncology Discovery Research and Early Development, Johnson & Johnson Pharmaceutical Research and Development, Janssen Pharmaceutica, Beerse, Belgium

    X
  • Tim Perera,

    Affiliation: Oncology Discovery Research and Early Development, Johnson & Johnson Pharmaceutical Research and Development, Janssen Pharmaceutica, Beerse, Belgium

    X
  • Peter J. Parker,

    Affiliations: Protein Phosphorylation Laboratory, London Research Institute, Cancer Research UK, London, United Kingdom, Division of Cancer Studies, King's College School of Medicine, Guy's Hospital, London, United Kingdom

    X
  • Adrian L. Harris,

    Affiliation: Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

    X
  • Banafshé Larijani,

    Affiliation: Cell Biophysics Laboratory, London Research Institute, Cancer Research UK, London, United Kingdom

    X
  • Anthony Kong mail

    Anthony.kong@imm.ox.ac.uk

    Affiliation: Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom

    X
  • Published: December 21, 2010
  • DOI: 10.1371/journal.pbio.1000563

About the Authors

Merel Gijsen, Adrian L. Harris, Anthony Kong
Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
Peter King, Tim Perera
Oncology Discovery Research and Early Development, Johnson & Johnson Pharmaceutical Research and Development, Janssen Pharmaceutica, Beerse, Belgium
Peter J. Parker
Protein Phosphorylation Laboratory, London Research Institute, Cancer Research UK, London, United Kingdom
Peter J. Parker
Division of Cancer Studies, King's College School of Medicine, Guy's Hospital, London, United Kingdom
Banafshé Larijani
Cell Biophysics Laboratory, London Research Institute, Cancer Research UK, London, United Kingdom

Corresponding Author

Email: Anthony.kong@imm.ox.ac.uk

Competing Interests

Tim Perera and Peter King are employees and small share-holders of Johnson & Johnson Pharmaceutical Research & Development. This Competing Interest does not alter our adherence to all the PLoS Biology policies on sharing data and materials, or to the Creative Commons Attribution License in the event of publication.

Author Contributions

The author(s) have made the following declarations about their contributions: Conceived and designed the experiments: MG PK AK. Performed the experiments: MG PK AK. Analyzed the data: MG PK TP AK. Contributed reagents/materials/analysis tools: ALH BL AK. Wrote the paper: PK AK. Helped in the interpretation of data and suggested experiments: PJP ALH BL.